Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study

AIM: The aim of this study was to evaluate the efficacy of lurasidone in acute schizophrenia in Japan and other countries. METHODS: Subjects (aged 18–74 years) diagnosed with schizophrenia were randomized to lurasidone 40 mg/day or placebo. The primary efficacy endpoint was change from baseline on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyo, Masaomi, Ishigooka, Jun, Nakamura, Masatoshi, Sakaguchi, Reiko, Okamoto, Keisuke, Mao, Yongcai, Tsai, Joyce, Fitzgerald, Alison, Nosaka, Tadashi, Higuchi, Teruhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361730/
https://www.ncbi.nlm.nih.gov/pubmed/33890388
http://dx.doi.org/10.1111/pcn.13221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361730/
https://www.ncbi.nlm.nih.gov/pubmed/33890388
http://dx.doi.org/10.1111/pcn.13221

Ejemplares similares